drugset / Trial / NCT05574985
Recombinant Omicron-Delta COVID-19 Vaccine (CHO Cell)
Completed
272 enrolled
Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
The First Affiliated Hospital of Bengbu Medical University · collab
RandomizedParallel-groupOpen-labelPrevention
Summary
Popular topic:A Clinical Study of Recombinant Omicron-Delta COVID-19 Vaccine (CHO Cell) Overall design:The study was designed as a randomized, open and controlled study. Study population: People aged 18 years and above and 6-15 months after the completion of basic immunization or 6-9 months after the completion of enhanced immunization with the new coronal prototype vaccine. Test groups:Study group；Control group；Observation group ①；Observation group ②
Timeline
- Start
- 2022-08-29
- Primary completion
- 2022-10-09
- Completion
- 2023-03-18
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Inactivated COVID-19 vaccine (Vero Cell) | Vaccine | — | — |
| Subject | Recombinant Omicron-Delta COVID-19 Vaccine (CHO Cell) | Vaccine | 25 ug | — |